Executive Order Category Rationale

Justification

This executive order is primarily focused on improving medical research infrastructure and healthcare guidance for patients and doctors regarding marijuana and CBD products. The order explicitly states "it is the policy of my Administration to increase medical marijuana and CBD research to better inform patients and doctors," and extensively references FDA findings, healthcare practitioners, and patient populations including veterans and seniors. The order directs HHS, NIH, FDA, and CMS to "develop research methods and models utilizing real-world evidence to improve access to hemp-derived cannabinoid products" and to "inform standards of care." While the order involves rescheduling marijuana under the CSA, this is framed as a means to advance medical research and patient health outcomes rather than as a primary regulatory or law enforcement objective.

Secondary Categories

• Regulatory Reform & Oversight

  The order directly addresses rescheduling marijuana under the Controlled Substances Act and developing a new regulatory framework for hemp-derived cannabinoid products, including THC limits and labeling standards.

• Justice & Law Enforcement

  The order directs the Attorney General to complete rulemaking to reschedule marijuana to Schedule III of the CSA, implicating federal drug control policy and enforcement priorities.